Re-evaluation of the cardiovascular safety of rosiglitazone

VernacularTitle:再评罗格列酮的心血管安全性
Author: Yanming CHEN ; Xixiang TANG ; Longyi ZENG
Publication Type:Journal Article
Keywords: Rosiglitazone; Diabetes mellitus,type 2; Cardiovascular events; Safety
From: Chinese Journal of Endocrinology and Metabolism 2014;30(6):456-459
CountryChina
Language:Chinese
Abstract: Rosiglitazone is one of thiazolidinediones (TZD),an antidiabetic agent which improves insulin sensitivity,but the cardiovascular safety of the drug remains controversial.The new re-evaluation of the RECORD trial has suggested that rosiglitazone-containing drugs do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines,such as mefformin and sulfonylurea.The post hoc analysis of the BARI 2D also indicates that rosiglitazone may not relate with the increased risk of major ischemic cardiovascular events.According to these new results,there is no clear evidence that rosiglitazone may increase cardiovascular risk.The U.S.Food and Drug Administration announced in July 2013 that it is requiring the removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines.